Mr. Keith Berman MPH, MBA

GLG News^SM Analyses by Keith Berman

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

Grifols Forges Ahead With New Plant Construction; Closing of Talecris Deal Nears

February 22, 2011

Analysis of:Grifols Starts Construction of a New Plasma Fractionation Plant in Barcelona (Parets Del Valles) | www.prnewswire.com

Adhering closely to plans approved by the company's Board in late 2007, Grifols SA announced it will shortly start construction of a new plasma fractionation plant in Barcelona.  This facility will have an annual capacity of 1 million liters, expandable to 2 million liters.  Altogether, the company's fractionation capacity in 2014 could reach 6.3 million liters -- not including another 4.2 million liters of capacity it will add with its pending deal to acquire Talecris Biotherapeutics.

Talecris Deal Just Weeks Away, Grifols Forges Ahead With New Plant Construction

February 19, 2011

Analysis of:Grifols Starts Construction of a New Plasma Fractionation Plant in Barcelona (Parets Del Valles) | www.prnewswire.com

Adhering closely to plans approved by the company's Board in late 2007, Grifols SA announced it will shortly start construction of a new plasma fractionation plant in Barcelona.  This facility will have an annual capacity of 1 million liters, expandable to 2 million liters.  Altogether, the company's fractionation capacity in 2014 could reach 6.3 million liters -- not including another 4.2 million liters of capacity it will add with its pending deal to acquire Talecris Biotherapeutics.

Grifols Launches 10% IVIG, Leveling Playing Field with Baxter, CSL and Talecris

November 23, 2010

Analysis of:Grifols Announces U.S. Launch of Flebogamma DIF 10% IVIG | www.prnewswire.com

With its new Flebogamma DIF 10% IVIG product, literally overnight Grifols becomes a more formidable competitor for market leaders Baxter International, CSL and Talecris Biotherapeutics.The Barcelona-based company has done remarkably well in the outsized U.S. market with a marginally less desirable 5% IVIG product, posting recent double-digit growth.  This new high-purity 10% product instantly erases that disadvantage and positions Grifols to compete effectively for years to come.

IVIG Researchers: Consider Using Talecris' GAMUNEX More Aggressively in CIDP

June 4, 2010

Analysis of:Timing and Course of Clinical Response to Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyradiculoneuropathy | www.ncbi.nlm.nih.gov

A new analysis of the successful Talecris-sponsored crossover trial of GAMUNEX IVIG to treat CIDP revealed that only about half of responders improved at 3 weeks, while the other half didn't respond until week 6 after a second course of IVIG.  The investigators proposed that treatment with 2 doses of IVIG every 3 weeks may be required for initial improvement in some patients.  They also made a strong case for continued maintenance IVIG therapy to achieve a maximal therapeutic response.

Talecris Biotherapeutics Proposes IPO; Hits Favorable Timing Window

September 23, 2009

Analysis of:Talecris Joins Crowd of Stock Offerings | www.newsobserver.com

Talecris Biotherapeutics and its two private equity owners -- Cerberus Capital Management and Ampersand Ventures -- are counting on the third time being the charm with their new IPO slated to sell 44.7 million shares at a target price of $18 to $20 each. About $515 million of these funds are earmarked to pay off loans, with the balance available to bolster commercialization activities, advance the company's ambitious R & D pipeline and help fund capacity expansion.

View All GLG News ^SM Analyses by Keith Berman